135 related articles for article (PubMed ID: 16178496)
41. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
42. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
44. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
45. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
[TBL] [Abstract][Full Text] [Related]
46. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.
Jacobson TA; Wertz DA; Hoy T; Kuznik A; Grochulski D; Cziraky M
Mayo Clin Proc; 2008 Dec; 83(12):1316-25. PubMed ID: 19046550
[TBL] [Abstract][Full Text] [Related]
47. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
48. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Glueck CJ; Rawal B; Khan NA; Yeramaneni S; Goldenberg N; Wang P
Metabolism; 2009 Feb; 58(2):233-8. PubMed ID: 19154957
[TBL] [Abstract][Full Text] [Related]
49. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
Romero R; Calviño J; Rodriguez J; Sánchez-Guisande D
Nephrol Dial Transplant; 2000 Sep; 15(9):1446-9. PubMed ID: 10978406
[TBL] [Abstract][Full Text] [Related]
50. [Aggressive therapy and combination therapy in severe hyperlipidemia].
Kostner KM
Wien Med Wochenschr; 1999; 149(5-6):146-8. PubMed ID: 10408007
[TBL] [Abstract][Full Text] [Related]
51. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
Andrén L; Andreasson A; Eggertsen R
Eur J Clin Pharmacol; 2007 Oct; 63(10):913-6. PubMed ID: 17701167
[TBL] [Abstract][Full Text] [Related]
52. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
53. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
[TBL] [Abstract][Full Text] [Related]
54. Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men.
Mauger JF; Couture P; Paradis ME; Lamarche B
Atherosclerosis; 2005 Jan; 178(1):157-63. PubMed ID: 15585213
[TBL] [Abstract][Full Text] [Related]
55. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
[TBL] [Abstract][Full Text] [Related]
56. Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic.
Valdez CA; Ulrich H
J Manag Care Pharm; 2005; 11(6):499-504. PubMed ID: 15998167
[TBL] [Abstract][Full Text] [Related]
57. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Acta Cardiol; 2006 Jun; 61(3):263-9. PubMed ID: 16869445
[TBL] [Abstract][Full Text] [Related]
58. No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin.
Singhal MK; Bhaskaran S; Szabo T; La Rosa R
Perit Dial Int; 1999; 19(1):89-91. PubMed ID: 10201354
[No Abstract] [Full Text] [Related]
59. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
60. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
Lloret R; Ycas J; Stein M; Haffner S;
Am J Cardiol; 2006 Sep; 98(6):768-73. PubMed ID: 16950182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]